http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109568336-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 |
| filingDate | 2018-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109568336-B |
| titleOfInvention | Composition of platinum compound and chondroitin sulfate and application thereof |
| abstract | The invention relates to the field of organic synthesis and pharmaceutical chemistry, in particular to a composition of a platinum compound and chondroitin sulfate and application thereof. The platinum compound and the chondroitin sulfate disclosed by the invention are combined and used for administration, can be applied to preparation of antitumor drugs, and pharmacological experiments show that the platinum compound and the chondroitin sulfate have obvious antitumor effects on different cancer cells, and specifically comprise the following components: the composition combining the platinum compound and the chondroitin sulfate has an obvious anti-tumor effect, and the toxic and side effects caused by single administration of the platinum compound and the chondroitin sulfate can be effectively relieved by combining the composition; the combined composition has potential development value for novel high-efficiency, low-toxic-side-effect and drug-resistance anti-tumor drugs. |
| priorityDate | 2018-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.